Dashboard
Manage Tickers

BTAIBioXcel Therapeutics, Inc.

Nasdaq bioxceltherapeutics.com


$ 2.58 $ 0.01 (0.39 %)    

Friday, 03-May-2024 15:58:27 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 2.57
$ 2.63
$ 0.00 x 0
$ 0.00 x 0
$ 2.57 - $ 2.64
$ 1.91 - $ 29.56
147,562
na
74.86M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-22-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-16-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-11-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-10-2021 03-31-2021 10-Q
13 03-12-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-09-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-12-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-14-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bioxcel-therapeutics-announces-late-breaking-abstract-on-preliminary-findings-from-phase-2-investigator-sponsored-trial-of-bxcl701-and-keytruda-in-metastatic-pancreatic-ductal-adenocarcinoma-selected-for-presentation-at-2024-asco-annual-meeting
BioXcel Therapeutics Announces Late-Breaki...
04/24/2024 14:33:01

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's...

hc-wainwright--co-reiterates-buy-on-bioxcel-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on BioX...
04/23/2024 10:28:58

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

bioxcel-therapeutics-reveals-plan-for-evaluating-bxcl501-in-the-at-home-setting-to-expand-its-market-potential
BioXcel Therapeutics Reveals Plan For Eval...
04/22/2024 11:08:00

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No...

bioxcel-therapeutics-announced-details-regarding-the-planned-design-of-its-upcoming-tranquility-in-care-phase-3-trial-of-bxcl501-for-agitation-associated-with-alzheimers-dementia
BioXcel Therapeutics Announced Details Reg...
04/10/2024 11:06:07

bioxcel-therapeutics-shares-are-trading-lower-after-the-company-announced-a-25-million-registered-direct-offering
BioXcel Therapeutics shares are trading lo...
03/25/2024 11:23:13

bioxcel-therapeutics-announces-25m-registered-direct-offering
BioXcel Therapeutics Announces $25M Regist...
03/25/2024 11:03:29

BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence...

hc-wainwright--co-reiterates-buy-on-bioxcel-therapeutics-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on BioX...
03/18/2024 10:54:31

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $1...

bioxcel-therapeutics-reported-that-the-european-patent-office-granted-the-companys-european-patent-covering-the-use-of-dexmedetomidine-administered-sublingually-to-treat-agitation-in-individuals-with-dementia
BioXcel Therapeutics Reported That The Eur...
03/15/2024 11:02:05

The patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and...

canaccord-genuity-maintains-buy-on-bioxcel-therapeutics-lowers-price-target-to-7
Canaccord Genuity Maintains Buy on BioXcel...
03/14/2024 11:26:33

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price targe...

b-of-a-securities-maintains-buy-on-bioxcel-therapeutics-lowers-price-target-to-7
B of A Securities Maintains Buy on BioXcel...
03/13/2024 14:32:56

B of A Securities analyst Geoff Meacham maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target ...

bioxcel-therapeutics-shares-are-trading-higher-after-the-company-reported-better-than-expected-q4-gaap-eps-results
BioXcel Therapeutics shares are trading hi...
03/12/2024 13:08:04

bioxcel-therapeutics-cash-and-cash-equivalents-totaled-652m-which-is-expected-to-provide-cash-runway-through-mid-2024
BioXcel Therapeutics' Cash And Cash Equiva...
03/12/2024 11:04:41

bioxcel-therapeutics-q4-gaap-eps-076-beats-091-estimate-sales-37600k-miss-71000k-estimate
BioXcel Therapeutics Q4 GAAP EPS $(0.76) B...
03/12/2024 11:03:31

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-march-12-2024
Earnings Scheduled For March 12, 2024
03/12/2024 09:35:47

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

bioxcel-therapeuticss-earnings-outlook
BioXcel Therapeutics's Earnings Outlook
03/11/2024 15:02:41

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/27/2024 21:31:08

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
02/14/2024 17:31:14

why-bioxcel-therapeutics-shares-are-rising-tuesday
Why BioXcel Therapeutics Shares Are Rising...
02/13/2024 17:56:08

BioXcel Therapeutics shares surge 25.1% as the company terminates its proposed public offering and shifts focus to upcoming FDA...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
02/13/2024 17:31:12

bioxcel-therapeutics-terminates-60m-proposed-public-offering
BioXcel Therapeutics Terminates $60M Propo...
02/13/2024 14:04:00

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION